Efficacy of risperidone on positive features of schizophrenia

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Dopaminergic hyperactivity mediated via D2 receptors is implicated in the etiology of positive symptoms of schizophrenia, but selective D2 antagonists provide imperfect therapy. This article describes a subanalysis of a trial of risperidone, a combined 5-HT(2A)/D2 antagonist, in 513 patients with DSM- III-R chronic schizophrenia. Risperidone at 2, 6, 10, and 16 mg/day was compared with placebo and haloperidol 20 mg/day. All doses of risperidone and the 20-mg dose of haloperidol were superior to placebo (mean change from baseline on the PANSS positive and general psychopathology subscales). The 6- mg dose of risperidone also produced significantly more improvement than haloperidol 20 mg. We conclude that risperidone is an effective drug for patients with positive features of schizophrenia.

Original languageEnglish (US)
Pages (from-to)18-21
Number of pages4
JournalJournal of Clinical Psychiatry
Volume55
Issue number5 SUPPL.
StatePublished - Jun 20 1994
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Fingerprint Dive into the research topics of 'Efficacy of risperidone on positive features of schizophrenia'. Together they form a unique fingerprint.

  • Cite this